Allakos Stock Price, News & Analysis (NASDAQ:ALLK) $2.62 +0.34 (+14.91%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.36▼$2.6550-Day Range$1.72▼$2.5052-Week Range$1.48▼$8.73Volume1.65 million shsAverage Volume1.00 million shsMarket Capitalization$229.20 millionP/E RatioN/ADividend YieldN/APrice Target$11.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Allakos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside333.5% Upside$11.36 Price TargetShort InterestHealthy3.92% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.93Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.81 out of 5 starsMedical Sector51st out of 952 stocksPharmaceutical Preparations Industry11th out of 434 stocks 3.3 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.36, Allakos has a forecasted upside of 333.5% from its current price of $2.62.Amount of Analyst CoverageAllakos has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.92% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allakos has recently decreased by 13.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 2.7 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Allakos this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders28.07% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.87) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allakos Stock (NASDAQ:ALLK)Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.Read More ALLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLK Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comAllakos (NASDAQ:ALLK) Stock Rating Reaffirmed by JMP SecuritiesNovember 28, 2023 | markets.businessinsider.comBuy Rating for Allakos: Anticipating Lirentelimab’s Market Catalyst and Blockbuster PotentialDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 16, 2023 | bizjournals.comOhio's VC vehicle has attracted investment and jobs – but could cost taxpayers $100MNovember 15, 2023 | msn.comAllakos GAAP EPS of -$0.52 misses by $0.06November 15, 2023 | markets.businessinsider.comPromising Developments and Solid Financials Drive Buy Rating for Allakos: An Analysis of Lirentelimab Trials and Investment PotentialNovember 14, 2023 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on Allakos (ALLK)December 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 13, 2023 | seekingalpha.comAllakos files to sell up to $250M worth of its common stockNovember 13, 2023 | finance.yahoo.comAllakos Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | finance.yahoo.comAllakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023November 6, 2023 | finance.yahoo.comFollowing a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional ownersNovember 2, 2023 | msn.comAlloVir GAAP EPS of -$0.39 beats by $0.01October 5, 2023 | msn.comAllakos (ALLK) Price Target Increased by 23.96% to 10.12September 27, 2023 | msn.comAllokos stock jumps 16% as JMP starts coverage at market outperformSeptember 27, 2023 | msn.comAllakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock UpsideSeptember 27, 2023 | finance.yahoo.comWhy Shares of Allakos Are Up WednesdaySeptember 27, 2023 | markets.businessinsider.comPromising Prospects for Allakos’ Innovative Monoclonal Antibodies: A Strong Buy RatingSeptember 18, 2023 | msn.comScratching The Surface: Allakos' Novel Take On UrticariaAugust 31, 2023 | finanznachrichten.deAllakos Inc.: Allakos Appoints Neil Graham to its Board of DirectorsAugust 30, 2023 | finance.yahoo.comAllakos Appoints Neil Graham to its Board of DirectorsAugust 11, 2023 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Their Hold Rating for Allakos (ALLK)August 10, 2023 | markets.businessinsider.comAllakos (ALLK) Initiated with a Sell at BarclaysAugust 9, 2023 | finance.yahoo.comAllakos Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | investing.comAllakos (ALLK) Earnings Dates & ReportsSee More Headlines Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees123Year FoundedN/APrice Target and Rating Average Stock Price Target$11.36 High Stock Price Target$22.00 Low Stock Price Target$1.50 Potential Upside/Downside+333.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-319,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.29% Return on Assets-49.61% Debt Debt-to-Equity RatioN/A Current Ratio9.31 Quick Ratio9.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book0.72Miscellaneous Outstanding Shares87,480,000Free Float62,921,000Market Cap$229.20 million OptionableNot Optionable Beta0.68 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Robert Alexander Ph.D. (Age 53)CEO & Director Comp: $1.46MDr. Adam L. Tomasi Ph.D. (Age 53)President Comp: $1.11MMr. Baird Radford III (Age 53)Chief Financial Officer Comp: $708.26kMs. Mary Cromwell Ph.D.Chief Technical OfficerDr. Craig Paterson M.D. (Age 58)Chief Medical Officer Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsMore ExecutivesKey CompetitorsAldeyra TherapeuticsNASDAQ:ALDXVerastemNASDAQ:VSTMVerrica PharmaceuticalsNASDAQ:VRCAGossamer BioNASDAQ:GOSSImmutepNASDAQ:IMMPView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 6,643 shares on 11/24/2023Ownership: 0.040%Jacobs Levy Equity Management Inc.Sold 134,463 shares on 11/17/2023Ownership: 0.035%Sectoral Asset Management Inc.Bought 335,822 shares on 11/15/2023Ownership: 0.886%AQR Capital Management LLCBought 53,199 shares on 11/15/2023Ownership: 0.083%Legal & General Group PlcSold 8,107 shares on 11/15/2023Ownership: 0.035%View All Institutional Transactions ALLK Stock Analysis - Frequently Asked Questions Should I buy or sell Allakos stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLK shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price target for 2024? 7 analysts have issued 1 year price targets for Allakos' stock. Their ALLK share price targets range from $1.50 to $22.00. On average, they anticipate the company's share price to reach $11.36 in the next year. This suggests a possible upside of 333.5% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2023? Allakos' stock was trading at $8.42 at the start of the year. Since then, ALLK stock has decreased by 68.9% and is now trading at $2.62. View the best growth stocks for 2023 here. Are investors shorting Allakos? Allakos saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,430,000 shares, a drop of 13.2% from the October 31st total of 3,950,000 shares. Based on an average daily volume of 960,600 shares, the short-interest ratio is presently 3.6 days. View Allakos' Short Interest. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). What ETF holds Allakos' stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager. Who are Allakos' major shareholders? Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include RiverVest Venture Management LLC (5.74%), Redmile Group LLC (4.76%), Blackstone Inc. (4.71%), Vontobel Holding Ltd. (0.89%), Sectoral Asset Management Inc. (0.89%) and Citigroup Inc. (0.52%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALLK) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.